Abstract
BackgroundRituximab (RTX) is a B-cell depleting antibody widely used to treat rheumatoid arthritis (RA). Responses to RTX are in close correlation with the efficacy of B-cell depletion. Therefore the determination...
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have